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Purpose
Celecoxib, a highly selective cyclooxygenase-2 inhibitor, regulates apoptosis of several
types of human cancer cells. The purpose of this study was to investigate whether
celecoxib in combination with paclitaxel modulates apoptosis of ovarian cancer cells,
and to identify the signal pathway by which celecoxib mediates apoptosis.
Materials and Methods
OVCAR-3 cells were exposed to paclitaxel (20 μM) in the absence or presence of 
celecoxib (10 μM). Cell viability was evaluated using a Cell Counting Kit-8 assay. Apop-
tosis was evaluated using Annexin-V/7-aminoactinomycin D staining and a cellular
DNA fragmentation enzyme-linked immunosorbent assay. Caspase-3, -9, and cleav-
age of poly ADP-ribose polymerase (PARP) were determined by western blotting. 
Expression of nuclear factor-κB (NF-κB) and vascular endothelial growth factor (VEGF)
and Akt activation were assessed using reverse transcriptase-polymerase chain 
reaction and western blotting.
Results
Celecoxib enhanced paclitaxel-induced growth inhibition of OVCAR-3 cells. Celecoxib
significantly increased paclitaxel-induced apoptosis of OVCAR-3 cells. Pretreatment
with celecoxib also increased activation of caspase-9, -3 and cleaved PARP following
paclitaxel-treatment. Exposure of OVCAR-3 cells to celecoxib in combination with 
paclitaxel resulted in downregulation of NF-κB activation and VEGF expression. 
Furthermore, combining celecoxib and paclitaxel inhibited phosphorylation of Akt.
Conclusion
OVCAR-3 cells were sensitized to paclitaxel-induced apoptosis by celecoxib through
downregulation of NF-κB and Akt activation, suggesting that celecoxib may work 
synergistically with paclitaxel to inhibit different targets and ultimately produce 
anticancer effects. Combining celecoxib with paclitaxel may prove beneficial in the
clinical treatment of ovarian cancer.
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Introduction
Ovarian cancer is a leading cause of death in women
worldwide, in part because symptoms often are not observed
until the cancer has spread extensively. Thus, the prognosis
for ovarian cancer is generally very poor and the mortality
rate is high. Patients with ovarian cancer generally acquire
resistance to chemotherapeutic agents and development of
recurrent chemotherapy resistance is a common outcome of
the cancer therapy, even in patients who have an initially
positive clinical response to chemotherapy [1]. As such, 
developing a novel strategy against chemoresistance is a 
central issue.
Paclitaxel, isolated from the bark of Taxus brevifolia, is one
of most potent chemotherapeutic agents against a wide 
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spectrum of human cancers, particularly advanced ovarian
and breast cancers [2]. Several studies have demonstrated
that it induces apoptosis in various solid tumor cells. 
However, paclitaxel chemotherapy has had limited success
because of dose-limiting toxicity and eventual drug resist-
ance in patients. The molecular mechanisms of paclitaxel 
resistance are not well understood, although multifactorial
mechanisms involving the activation of nuclear factor-κB
(NF-κB), upregulation of cytoprotective pathways such as
Akt and mitogen-activated protein kinase (MAPK), and 
alterations in β-tubulin isotypes have been suggested [3]. 
In addition, paclitaxel has been implicated in regulating 
targeted intracellular proteins that promote cell survival and
alterations in the intrinsic apoptotic pathway [4].
Accumulating evidence suggests that activated NF-κB is
critical in the development of drug resistance in cancer cells
[5]. Therefore, agents that inhibit NF-κB function might be
considered in combination with paclitaxel as an adjuvant 
approach for treatment of ovarian cancer.
Celecoxib, a class of non-steroidal anti-inflammatory drug,
constitutes a potent and specific inhibitor of the human 
cyclooxygenase-2 (COX-2). COX-2 is constitutively overex-
pressed in many human premalignant, malignant, and
metastatic epithelial tumors [6]. Upregulated expression of
COX-2 may promote tumor growth through inhibition of
apoptosis [7]. Moreover, COX-2 can be regulated by expres-
sion of vascular endothelial growth factor (VEGF), one of the
most potent angiogenic factors known. In addition, one of
the major positive regulators of COX-2 is NF-κB [8]. There-
fore, the possibility of using COX-2 inhibitors as part of 
cancer therapy has gained interest. Mounting evidence 
suggests that celecoxib possesses potent antiproliferative, 
antiangiogenic, antimetastatic and proapoptotic properties
in vitro as well as in vivo [7-9]. Celecoxib clinically promotes
chemosensitivity and radiosensitivity of cancer cells. Cele-
coxib significantly prevents the development of chemoresis-
tance in the breast cancer cell line MCF-7 [10], decreases
NF-κB DNA binding, and inhibits cell growth in hepatoma
cell lines [11]. However, though the anticancer effects of 
paclitaxel and celecoxib have been evaluated comprehen-
sively in a variety of human cancers, the potential role of
these compounds used in combination as an anticancer treat-
ment has not been tested in ovarian cancer cells.
The present study investigated the potential role of 
celecoxib on paclitaxel-induced apoptosis in an ovarian 
cancer cell line. The results show that when celecoxib and 
paclitaxel are combined they have an additive or synergistic
anticancer effect.
Materials and Methods
1. Cell culture
Human epithelial ovarian cancer cell line OVCAR-3 was
cultured in RPMI-1640 medium supplemented with 10%
fetal bovine serum (FBS), 100 U/mL of penicillin and 100
μg/mL of streptomycin. The cells were incubated in a 
humidified atmosphere containing 5% CO2 at 37°C.
2. Cell viability assay
Cell viability was measured using the Cell Counting Kit-8
(CCK-8) assay (Dojindo Laboratories, Kumamoto, Japan).
Cells were seeded in a 96-well flat-bottomed plate (2×103 cells
in 100 μL per well). The cells were incubated overnight to
allow for cell attachment and recovery and then exposed to
paclitaxel (Bristol-Myers Squibb, New York, NY) and 
celecoxib (Pfizer Inc., New York, NY) for 6, 24, and 48 hours.
Ten microliters of cell CCK-8 solution was added to each
well, the cells were incubated for another two hours, and 
absorbance at 450 nm was measured with a microplate
reader.
3. VEGF gene expression analysis by reverse transcriptase-
polymerase chain reaction (PCR)
OVCAR-3 (2×106) cells were pretreated with celecoxib (10
μM) for 1 hour before addition of paclitaxel (20 μM) for 6
hours. Total RNA was extracted using the Trizol reagent 
(Invitrogen, Grand Island, NY). One microgram of total RNA
was converted to cDNA using oligo-dT as a primer and 
M-MLV reverse transcriptase (Invitrogen). PCR amplifica-
tion proceeded as follows: 33 thermocycles at 94°C for 30 
seconds, 55°C for 30 seconds, and 72°C for 30 seconds, using
oligonucleotides specific to human VEGF (forward: tga cag
gga aga gga gga ga, reverse: tgg ttt caa tgg tgt gag ga) and
human β-actin (forward: agg cca acc gcg aga aga tga cc, 
reverse: gaa gtc cag ggc gac gta gca c). Amplified fragments
were analyzed using a 1% agarose gel and photographed
over UV light. β-Actin was used as an internal control to
compare data from different films.
4. Western blot analysis
Protein samples were lysed with 0.5% Nonidet P-40 and
resuspended in complete lysis buffer. Proteins with 20 
micrograms of cell lysate were directly separated by 8% 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
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and transferred to polyvinylidene difluoride membranes
(Millipore, Etten-Leur, The Netherlands). The membranes
were blocked with 5% (w/v) non-fat milk in Tris buffered
saline-Tween 20 (TBST) and incubated with primary antibod-
ies (rabbit anti-p-NF-κB p65, anti-caspase-9, anti-poly 
ADP-ribose polymerase [PARP], anti-phospho-Akt and anti-
γ-tubulin antibody; Cell Signaling, Beverly, MA) overnight
at 4°C. The membrane was washed three times with TBST
and then incubated with horseradish peroxidase (HRP)-
linked anti-rabbit IgG secondary antibody for one hour at
room temperature. After three 15-minute TBST washing
steps, the protein was visualized on photography film (Phar-
macia, Uppsala, Sweden) by enhanced chemiluminescence.
The blots were reprobed with anti-γ-tubulin antibody for
loading control.
5. Detection of NF-κB activity
Activation of the NF-κB p65 transcription factor subunits
was determined using Trans AM kits according to manufac-
turer’s instructions (Active Motif, Rixensard, Belgium). 
Nuclear extracts were prepared in hypotonic buffer and
lysed with 0.5% Nonidet P-40. Concentration of the activated
transcription factor was detected using an enzyme-linked
immunosorbent assay (ELISA)-based method. The nuclear
extract was incubated for 1 hour with a plate coated with an
oligonucleotide that corresponded to a transcription factor
consensus site. The wells were washed and incubated with
an antibody against the indicated transcription factor 
subunit. An anti-rabbit IgG HRP conjugate was added, then
the developing solution was added, and finally the colori-
metric reaction was measured at 450 nm. The experiment
was performed in triplicate.
6. Immunofluorescence
Cells were plated on eight-chamber slides (Nunc,
Rochester, NY). After treatment, cells were rinsed in 
phosphate buffered saline (PBS) and fixed by incubation with
4% formaldehyde in PBS for 15 minutes at room tempera-
ture. After an additional wash with PBS, cells were perme-
abilized with PBS containing 0.25% Triton X-100 and then
blocked in PBS containing 1% bovine serum albumin and
10% goat serum. The cells were incubated with polyclonal
anti-p65 antibody in primary antibody dilution (1:200) buffer
overnight at 4°C. After PBS washing, Alexa 488 (green) 
coupled secondary antibody (Invitrogen) was applied for 30
minutes at room temperature. Coverslips were mounted to
slides using ProLong Gold antifade reagent containing DAPI
and photographed using fluorescence microscopy.
7. Apoptosis assay
After exposure to celecoxib for 1 hour and incubation with
paclitaxel for an additional 48 hours, cells were harvested by
trypsinization. Cell density was adjusted to 1×106 cells per
mL in PBS. Apoptosis was determined by staining with 
annexin V-FITC and 7-aminoactinomycin D (7-AAD) (BD
PharMingen, San Diego, CA). Cells were analyzed by flow
cytometry on a FACScan (Becton Dickinson, Mountain View,
CA) using CellQuest software. In some experiments, 
apoptosis was also determined by ELISA using a DNA 
fragmentation kit (Roche Applied Science, Indianapolis, IN).
Cells were seeded at a density of 2×104 cells per well in 
96-well plates. After 24 hours, the medium was changed to a
serum-free medium for at least 24 hours. To label DNA, the
medium was replaced with 10% FBS-Dulbecco’s modified
Eagle medium and 10 μM 5-bromo-2’-deoxyuridine (BrdU)
was added to each well and incubated for 24 hours. Cells
were treated with celecoxib for 1 hour and then incubated
with paclitaxel for an additional 48 hours. Cells were then
lysed in 200 μL incubation buffer, and soluble DNA 
fragments were quantified using cellular DNA fragmenta-
tion ELISA according to the manufacturer’s instructions. All
experiments were performed in triplicate.
8. Measurement of caspase-3 activity
Caspase-3 activity was assayed in cellular extracts using
the Caspase-3/CPP32 Colorimetric Assay kit (BioVision, 
Milpitas, CA) according to the manufacturer’s instructions.
Cell lysates were added to reaction mixtures containing 25
μM substrate DEVD-pNA. After incubation for 30 minutes,
a spectrophotometer equipped with a 405 nm filter was used
to detect caspase-3 activity. All experiments were performed
in triplicate.
9. Statistical analysis
Statistical significance was determined using student's 
t-test. Null hypotheses of no difference between means were
rejected if p-values were less than 0.05. Results are shown as
mean±SD.
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Results
1. Celecoxib increased paclitaxel-induced growth inhibi-
tion of human ovarian cancer cell line OVCAR-3
The potential effect of celecoxib on paclitaxel-induced 
ovarian cancer cell death was tested using a cell viability
assay (CCK-8 assay). A combination dose of 20 μM paclitaxel
and 10 μM celecoxib significantly reduced cell viability 
(Fig. 1). These results indicate that celecoxib can dramatically 
enhance paclitaxel-induced ovarian cancer cell death by 
reducing cell viability in the human ovarian cancer cell line
OVCAR-3.
2. Celecoxib enhanced paclitaxel-induced apoptosis in
OVCAR-3 cells
This study determined that celecoxib appears to increase
apoptosis in cells that have been exposed to paclitaxel. The
degree of apoptosis was assessed by measuring fluorescein
isothiocyanate-conjugated Annexin V and 7-AAD double
staining. Treatment with 20 μM of paclitaxel for 48 hours 
induced apoptosis (Fig. 2A). Celecoxib (10 μM) significantly
increased apoptosis induced by paclitaxel in OVCAR-3 cells.
The degree of apoptosis was analyzed using an ELISA that
measured the level of cellular DNA fragmentation. In accord
with previous findings, paclitaxel induced DNA fragmenta-
tion in OVCAR-3 cells. Treatment with celecoxib enhanced
DNA fragmentation induced by paclitaxel (Fig. 2B). To study
the effect of celecoxib and paclitaxel on the other ovarian 
cancer cell lines A2780 and SKOV3, we evaluated apotosis
by DNA fragmentation assay. When A2780 cells were treated
with a combination of celecoxib and paclitaxel, there was 
significant DNA fragmentation in a time-dependent manner
compared to paclitaxel treatment alone (Appendix 1A). On
the other hand, none of the combinations of celecoxib and
paclitaxel induced any synergistic effect in SKOV3 cells 
(Appendix 1B). Of note, in SKOV3 cells celecoxib increased
DNA fragmentation induced by paclitaxel for 36 hours.
These data suggest that celecoxib increased paclitaxel-
induced apoptosis in ovarian cancer cells.
3. Celecoxib increased paclitaxel-induced caspase a activa-
tion and PARP cleavage
Cleaved caspase-9 and caspase-3 activity were evaluated
by western blotting and colorimetric assay, respectively, to
confirm that apoptosis occurred in response to a combination
of celecoxib and paclitaxel. As shown in Fig. 3A, paclitaxel
induced cleaved caspase-9 after 24 hours. Celecoxib signifi-
cantly enhanced paclitaxel-induced activation of caspase-9
in OVCAR-3 cells. Moreover, combining celecoxib and 
paclitaxel significantly induced caspase-3 activation 24 hours
after treatment in OVCAR-3 cells (Fig. 3B).
Furthermore, PARPs are degraded by the caspase family
as a consequence of apoptosis and have been used as mark-
ers of apoptosis. Cleavage of PARP was observed after treat-
ment with a combination of paclitaxel and celecoxib (Fig. 3C).
In sum, these results indicate that celecoxib increases pacli-
taxel-induced apoptosis in OVCAR-3 cells through a 
caspase-dependent pathway.
Celecoxib increased paclitaxel-induced activation of 
caspase-3 and PARP in A2780 cells (Appendix 2). The 
combination of celecoxib and paclitaxel led to a marked 
increase of caspase-3 activity and up-regulation of cleaved
caspase-9 and cleaved PARP.
4. Celecoxib inhibited paclitaxel-induced NF-κB activation
and VEGF mRNA expression
Paclitaxel activates NF-κB in several cell lines, and was also
observed activating NF-κB in OVCAR-3 cells in this study
(Fig. 4A and B). On the other hand, celecoxib decreased 
paclitaxel-induced NF-κB activation. Treatment with 
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Fig. 1. Combined use of celecoxib and paclitaxel reduces
cell viability of the human ovarian cancer cell line OVCAR-3.
Cells were pretreated of celecoxib (10 μM) for 1 hour 
before addition of paclitaxel (20 μM) for 6 hours. Cell 
viability was measured using the Cell Counting Kit-8 
solution as described in the Materials and Methods section
of this paper. Results are representative of three experi-
ments. Data in the bar graph represent mean±SD. a)p＜0.05
vs. control, b)p＜0.05 vs. paclitaxel.
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Fig. 2. Celecoxib promotes paclitaxel-induced apoptosis in OVCAR-3 cells. Cells (1×105 cells/well) were pretreated with or
without celecoxib (10 μM) for 1 hour before addition of paclitaxel (20 μM). (A) Apoptosis was assessed by Annexin V-FITC/
7-aminoactinomycin D (7-AAD) staining after treating OVCAR-3 cells with paclitaxel for 48 hours, followed by fluorescence
activated cell sorting analysis. Gate settings distinguish between living (bottom left), necrotic (top left), early apoptotic 
(bottom right), and late apoptotic (top right) cells. In the right panel, the levels of apoptosis are presented as the fold increase
relative to the apoptosis of untreated OVCAR-3 cells. (B) Apoptosis was measured by cellular DNA fragmentation enzyme-
linked immunosorbent assay. Results are representative of three experiments. Data are presented as mean±SD. a)p＜0.05
vs. control, b)p＜0.05 vs. paclitaxel treated group.
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Fig. 3. Celecoxib enhances paclitaxel-induced caspase activation and poly ADP-ribose polymerase (PARP) cleavage. (A)
Cell lysates from cells incubated in the presence or absence of celecoxib (10 μM) for 1 hour following stimulation with pacli-
taxel (20 μM) for 24 hours were subjected to western blotting with anti-procaspase-9 antibody. (B) Caspase-3 activity was
measured by colorimetric assay. Data are presented as mean±SD. a)p＜0.05 vs. paclitaxel treated group. (C) Cells were 
incubated with or without celecoxib (10 μM) for 1 hour before addition of paclitaxel (20 μM). After 24 hours, cells were 
harvested and cleavage of PARP was analyzed by western blotting using anti-PARP antibody. The band intensities were
quantitated.
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Fig. 4. Celecoxib reduces the activation of nuclear factor-κB (NF-κB) and vascular endothelial growth factor (VEGF) mRNA
induced by paclitaxel. OVCAR-3 cells were pretreated of celecoxib (10 μM) for 1 hour before addition of paclitaxel (20 μM)
for 6 hours. The nuclear extract was collected. (A) Western blot analysis of pNF-κB p65. (B) The levels of active NF-κB family
members were determined using the Trans AM NF-κB kit according to the manufacturer’s instructions and reported as an
absorbance level of the colorimetric substrate. (C) NF-κB/p65 localization was visualized using an anti-NF-κB/p65 primary
antibody followed by an Alexa Fluor 488-conjugated detection antibody. (D) RNA was purified with Trizol as described in
the Materials and Methods section of this paper. One microgram of total RNAs was subjected to reverse transcriptase-poly-
merase chain reaction for detection of VEGF mRNA expression. Results are representative of three experiments. Data in the
bar graph represent mean±SD. a)p＜0.05 vs. control, b)p＜0.05 vs. paclitaxel.
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celecoxib alone decreased NF-κB activity. Immunofluores-
cence was performed against anti-p65 antibody to confirm
that  NF-κB is activated by paclitaxel (Fig. 4C). Pretreatment
with celecoxib clearly down-regulated NF-κB activation 
induced by paclitaxel. Celecoxib inhibited paclitaxel-induced
NF-κB activation in A2780 cells, as shown in the result from
OVCAR-3 cells (Appendix 3). Interestingly, paclitaxel could
not activate NF-κB in SKOV3 cells.
VEGF mRNA expression was significantly induced by 
paclitaxel. Celecoxib decreased paclitaxel-induced VEGF
mRNA expression 6 hours after treatment in OVCAR-3 cells
(Fig. 4D). These data indicate that the combined use of 
celecoxib and paclitaxel in OVCAR-3 cells led to the inhibi-
tion of NF-κB activation and VEGF mRNA expression.
5. Celecoxib decreased paclitaxel-induced Akt activation in
OVCAR-3 cells
We assessed potential molecular mechanisms supporting
a combination treatment synergism of effectiveness by 
combining celecoxib and paclitaxel with emphasis on deter-
mining whether the combination treatment enhanced inhi-
bition of the antiapoptotic signal transducers Akt. Celecoxib
inhibits Akt phosphorylation. This study confirmed that 
paclitaxel induces activation of Akt after 24 hours (Fig. 5) and
tested the effect of celecoxib on paclitaxel-induced Akt 
activation. Celecoxib pretreatment completely blocked the
phospho-Akt band in the combination, indicating that Akt
has a possible role in the synergistic effect of paclitaxel and
celecoxib.
Discussion
This study investigated the synergistic anticancer effect of
celecoxib and paclitaxel in the human ovarian cancer cell line
OVCAR-3. Celecoxib significantly enhanced apoptosis 
induced by paclitaxel. This celecoxib-mediated enhancement
of paclitaxel-induced apoptosis was accompanied by a 
significant increase in caspase activation and PARP cleavage.
Additionally, celecoxib inhibited paclitaxel-induced NF-κB
activation, VEGF expression and Akt phosphorylation in
OVCAR-3 cells. These results suggest that combining 
celecoxib with paclitaxel contributes to chemopreventive 
activity by inducing apoptosis of ovarian cancer cells.
Most cytotoxic chemotherapeutic drugs cause apoptosis in
cancer cells. However, certain tumor cells often escape apop-
tosis by overexpressing antiapoptotic proteins such as Bcl-2,
NF-κB, and Akt [12-14]. Despite advances in surgery and
chemotherapy, the survival rate of patients with ovarian 
cancer is still low because of drug resistance. The sensitivity
of cells to chemotherapeutic agent-induced apoptosis seems
to depend on the balance between proapoptotic and anti-
apoptotic signals. Paclitaxel is a microtubule-polymerizing
agent that is widely used in the treatment of solid tumors [2].
In addition, it inhibits endothelial cell migration, invasion, 
capillary tube formation and proliferation in vitro and
thereby leads to apoptosis in many cancers. A major disad-
vantage of paclitaxel is its dose-limiting toxicity and the 
development of drug resistance in patients. The development
of novel strategies that produce outcomes similar to pacli-
taxel, but without chemoresistance, would greatly enhance
the therapeutic effect of this drug. A recent study has shown
that the specific COX-2 inhibitor NS398 inhibited cell growth
and induced apoptosis in epithelial ovarian cancer cell lines
[15]. Several studies have investigated the effects of COX-2
inhibitors in combination with various chemotherapeutic
drugs. Celecoxib may be an effective potential chemopreven-
tive agent. According to a recent report, combining celecoxib
and paclitaxel produced disease stabilization in patients with
metastatic melanoma [16]. Similarly, combining this COX 
inhibitor with either paclitaxel or cisplatin had a synergistic
cytotoxic effect on human lung cancer cell lines [17]. This
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Fig. 5. Celecoxib reduces paclitaxel-induced Akt phospho-
rylation in OVCAR-3 cells. Cells were incubated with or
without celecoxib (10 μM) for 1 hour before addition of 
paclitaxel (20 μM). After 24 hours, cells were harvested and
Akt activation was analyzed by western blotting using
anti-phospho-Akt antibody. The band intensities were
quantitated.
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study showed that celecoxib significantly enhanced pacli-
taxel-induced apoptosis in OVCAR-3 and A2780 cells. The
proapoptotic effect of combining celecoxib with paclitaxel
was accompanied by a significant increase in caspase-3 
activation and PARP cleavage.
NF-κB is a ubiquitous transcription factor that controls the
expression of various genes associated with cell proliferation,
angiogenesis, metastasis, the cell cycle, and antiapoptosis. In
ovarian cancer, activation of NF-κB predicts poor prognosis
and disease progression and confers resistance to cisplatin-
induced apoptosis [18]. Increased NF-κB signaling by an 
inhibitor of NF-κB kinase B induces aggressiveness of ovar-
ian cancer. One study found that increased activity of NF-κB 
reduces paclitaxel-induced apoptosis in ovarian cancer cells
[19], while other studies have found that NF-κB mediates 
paclitaxel-induced apoptosis in ovarian cancer cells [20].
Thus the function of NF-κB in ovarian cancer depends on the
experimental system and tumor types. NF-κB can function
as a biphasic regulator, either suppressing or enhancing
ovarian cancer growth through the regulation of MAPK and
cellular apoptosis in parental or aggressive chemoresistant
variant cell lines [21]. Moreover, the NF-κB pathway 
contributes to chemoresistance in ovarian cancer cell lines.
In the present study, celecoxib increased paclitaxel-induced
apoptosis and down-regulated NF-κB activation induced by
paclitaxel in OVCAR-3 cells.
The current findings demonstrated down-regulation of 
paclitaxel-induced Akt activation by celecoxib in OVCAR-3
cells, and previous research has shown that the Akt survival
cascade is related to chemotherapeutic drug sensitivity. 
Recent studies have discovered several agents that inhibit
NF-κB and Akt, and these agents are currently in preclinical
or clinical trials. Treatment with LY294002, a specific 
inhibitor of phosphoinositide 3-kinase, results in enhance-
ment of paclitaxel-induced cytotoxicity through suppression
of NF-κB activity [22]. Paclitaxel appears to activate NF-κB
and Akt, which have critical roles in regulating cell survival,
proliferation, invasion and metastasis [2,20]. On the other
hand, celecoxib enhances apoptosis by interfering with 
various cell survival signaling pathways including NF-κB
and Akt [23]. Given that Akt suppresses apoptosis by 
activating NF-κB, NF-κB may be the crucial intermediary
step connecting Akt to the intrinsic susceptibility of cancer
cells to chemotherapeutic agents [22]. Whether paclitaxel-
induced up-regulation and celecoxib-induced down-regula-
tion of Akt is regulated only through NF-κB is neither clear
from these studies nor from ours. However, several studies
have shown that paclitaxel directly activates the survival
pathways such as Bcl-2, Akt, COX-2, or MAPK independ-
ently of NF-κB. This research attempted to determine the
pathways contributing to the synergism of paclitaxel and
celecoxib, and in doing so found that celecoxib downregu-
lated paclitaxel-induced NF-κB and Akt activation. These 
results indicate that NF-κB and Akt are central to the syner-
gism of paclitaxel and celecoxib.
COX-2 plays a significant role in tumor angiogenesis
through up-regulation of VEGF production in several cancer
cell lines [24]. VEGF appears contribute to angiogenesis in
ovarian cancer. A relationship between COX-2 and angio-
genesis has been noted, and hence COX-2 inhibitors may be
effective antiangiogenic agents. Several studies have 
reported that selective COX-2 inhibitors suppress VEGF 
expression, angiogenesis and metastasis in vivo. One pro-
posed mechanism of ovarian cancer prevention is a shared
pathway dependent on the suppression of NF-κB activity, 
resulting in a downregulation of inflammatory mediators
such as COX-2, VEGF, interleukin-8, and urokinase-type
plasminogen activator [25]. Specific COX-2 inhibition using
celecoxib suppressed serum VEGF concentrations in ovarian
cancer. Additionally, VEGF suppresses apoptosis in lung and
breast cancer cells and upregulates Bcl-2 levels in breast 
cancer cells, thus inhibiting apoptosis in both tumor cells and
vascular endothelial cells. Celecoxib in combination with 
paclitaxel is an attractive antiangiogenic and anticancer treat-
ment. These results confirm previous results indicating that
celecoxib promotes cell apoptosis coupled with down-regu-
lation of VEGF expression.
Conclusion
Data from signal transduction studies and in vitro cell 
culture experiments strongly suggest that celecoxib enhances
the antitumor activity of paclitaxel in ovarian cancer cells by
modulating NF-κB activation and Akt inhibition. These 
findings indicate that treatment with paclitaxel in combina-
tion with celecoxib may be an effective clinical strategy for
treating ovarian cancer, as combining the two agents 
enhances the antiangiogenic and antitumor effects of each
agent alone.
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Appendix 1. Effect of celecoxib on apoptosis in A2780 and SKOV3 cells. (A) A2780 and (B) SKOV3 cells (1×105 cells/well)
were pretreated with or without celecoxib (10 μM) for 1 hour before addition of paclitaxel (20 μM). Apoptosis was measured
by cellular DNA fragmentation enzyme-linked immunosorbent assay. Results are representative of three experiments. Data
are mean±SD.
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Appendix 2. Effect of celecoxib on paclitaxel-induced caspase-3 activation and poly ADP-ribose polymerase (PARP) cleavage.
(A) Cell lysates from cells incubated in the presence or absence of celecoxib (10 μM) for 1 hour following stimulation with
paclitaxel (20 μM) for 24 hours were subjected to western blotting with anti-procaspase-3 antibody. (B) Cells were incubated
with or without celecoxib (10 μM) for 1 hour before addition of paclitaxel (20 μM). After 24 hours, cells were harvested and
cleavage of PARP was analyzed by western blotting using anti-PARP antibody. The band intensities were quantitated.
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Appendix 3. Effect of celecoxib on nuclear factor-κB 
(NF-κB) activation. A2780 and SKOV3 cells were 
pretreated of celecoxib (10 μM) for 1 hour before addition
of paclitaxel (20 μM) for 6 hours. The nuclear extract was
collected. Western blot analysis of pNF-κB p65. The band
intensities were quantitated.
